Covered recipient · General Payments record
JOSHUA K SABARI
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$163,853.72
125 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $104,396.25 | 42 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $41,920.00 | 10 |
| Travel and Lodging | $14,793.43 | 30 |
| Food and Beverage | $2,744.04 | 43 |
By paying entity
PY2024 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| JAZZ PHARMACEUTICALS INC. | $63,317.05 | 34 |
| Janssen Biotech, Inc. | $31,684.78 | 29 |
| AstraZeneca Pharmaceuticals LP | $19,582.93 | 19 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $14,169.14 | 9 |
| Janssen Scientific Affairs, LLC | $6,783.73 | 4 |
| Daiichi Sankyo Inc. | $5,979.77 | 9 |
| Gilead Sciences, Inc. | $5,283.99 | 4 |
| Mirati Therapeutics, Inc. | $3,500.00 | 5 |
| EMD Serono, Inc. | $3,450.00 | 1 |
| Boehringer Ingelheim International GmbH | $2,590.00 | 1 |
| ABBVIE INC. | $2,419.00 | 2 |
| Genentech USA, Inc. | $1,670.49 | 3 |
| Janssen Global Services, LLC | $1,350.00 | 2 |
| BeiGene, Ltd. | $1,050.00 | 1 |
| PFIZER INC. | $1,000.00 | 1 |
| Tempus AI, Inc | $22.84 | 1 |
Page 2 of 3; records 51–100 of 125 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
JOSHUA K SABARI
NPI 1356638894 · CMS profile ID 1294108
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
NEW YORK, NY
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 3; records 51–100 of 125 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1356638894?year=2024&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- JOSHUA K SABARI, NPI 1356638894, CMS profile ID 1294108. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 125 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1356638894?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). JOSHUA K SABARI, NPI 1356638894, CMS profile ID 1294108. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 125 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1356638894?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- JOSHUA K SABARI, NPI 1356638894, CMS profile ID 1294108, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 125 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1356638894?year=2024&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
125 matching records · $163,853.72 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 125.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| JAZZ PHARMACEUTICALS INC. | $6,820.00 | 07/01/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1150211313 | CMS |
| Genentech USA, Inc. | $109.00 | 06/28/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133041473 | CMS |
| Genentech USA, Inc. | $1,515.00 | 06/28/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133041477 | CMS |
| Janssen Biotech, Inc. | $2,100.00 | 06/28/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078447511 | CMS |
| AstraZeneca Pharmaceuticals LP | $348.00 | 06/22/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1110532187 | CMS |
| AstraZeneca Pharmaceuticals LP | $56.28 | 06/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1110535804 | CMS |
| AstraZeneca Pharmaceuticals LP | $861.92 | 06/22/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1110546877 | CMS |
| JAZZ PHARMACEUTICALS INC. | $190.73 | 06/22/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1150211317 | CMS |
| JAZZ PHARMACEUTICALS INC. | $150.00 | 06/21/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1150211315 | CMS |
| JAZZ PHARMACEUTICALS INC. | $1,431.52 | 06/20/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1150211373 | CMS |
| JAZZ PHARMACEUTICALS INC. | $2,480.00 | 06/03/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1150211351 | CMS |
| AstraZeneca Pharmaceuticals LP | $14.79 | 06/02/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1110533750 | CMS |
| AstraZeneca Pharmaceuticals LP | $71.85 | 06/02/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1110550126 | CMS |
| Daiichi Sankyo Inc. | $31.27 | 06/02/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1089476969 | CMS |
| Genentech USA, Inc. | $46.49 | 06/02/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133041469 | CMS |
| JAZZ PHARMACEUTICALS INC. | $57.63 | 06/01/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1150211365 | CMS |
| Janssen Biotech, Inc. | $125.04 | 05/30/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078447870 | CMS |
| JAZZ PHARMACEUTICALS INC. | $4,960.00 | 05/29/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1150211341 | CMS |
| JAZZ PHARMACEUTICALS INC. | $229.50 | 05/28/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1150211345 | CMS |
| JAZZ PHARMACEUTICALS INC. | $1,439.00 | 05/28/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1150211361 | CMS |
| JAZZ PHARMACEUTICALS INC. | $1,368.90 | 05/28/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1150211363 | CMS |
| JAZZ PHARMACEUTICALS INC. | $124.89 | 05/24/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1150211343 | CMS |
| JAZZ PHARMACEUTICALS INC. | $605.24 | 05/22/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1150211311 | CMS |
| Mirati Therapeutics, Inc. | $700.00 | 05/22/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117170198 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $63.89 | 05/21/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117978018 | CMS |
| AstraZeneca Pharmaceuticals LP | $477.62 | 05/20/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1110552368 | CMS |
| AstraZeneca Pharmaceuticals LP | $1,370.00 | 05/18/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1126677418 | CMS |
| Janssen Biotech, Inc. | $3,500.00 | 05/17/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078452189 | CMS |
| AstraZeneca Pharmaceuticals LP | $2,055.00 | 05/06/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1110548250 | CMS |
| Gilead Sciences, Inc. | $1,520.00 | 05/03/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133599297 | CMS |
| Janssen Biotech, Inc. | $1,400.00 | 05/03/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078446569 | CMS |
| JAZZ PHARMACEUTICALS INC. | $127.11 | 05/02/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1150211347 | CMS |
| JAZZ PHARMACEUTICALS INC. | $127.11 | 05/02/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1150211349 | CMS |
| JAZZ PHARMACEUTICALS INC. | $3,100.00 | 04/29/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1150211353 | CMS |
| AstraZeneca Pharmaceuticals LP | $2,055.00 | 04/23/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1110534820 | CMS |
| AstraZeneca Pharmaceuticals LP | $63.45 | 04/21/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1126677964 | CMS |
| AstraZeneca Pharmaceuticals LP | $135.00 | 04/19/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1110541245 | CMS |
| Gilead Sciences, Inc. | $133.99 | 04/19/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133794673 | CMS |
| Mirati Therapeutics, Inc. | $700.00 | 04/19/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117170203 | CMS |
| Boehringer Ingelheim International GmbH | $2,590.00 | 04/17/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117978026 | CMS |
| Janssen Scientific Affairs, LLC | $33.73 | 04/12/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078856004 | CMS |
| JAZZ PHARMACEUTICALS INC. | $3,720.00 | 04/01/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1150211329 | CMS |
| JAZZ PHARMACEUTICALS INC. | $5,580.00 | 04/01/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1150211335 | CMS |
| AstraZeneca Pharmaceuticals LP | $3,425.00 | 03/31/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1110552526 | CMS |
| JAZZ PHARMACEUTICALS INC. | $632.35 | 03/29/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1150211357 | CMS |
| JAZZ PHARMACEUTICALS INC. | $1,400.78 | 03/28/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1150211359 | CMS |
| BeiGene, Ltd. | $1,050.00 | 03/27/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1120865852 | CMS |
| JAZZ PHARMACEUTICALS INC. | $108.80 | 03/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1150211337 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $44.74 | 03/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117978016 | CMS |
| JAZZ PHARMACEUTICALS INC. | $13.80 | 03/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1150211339 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $2,214,121.14 | 94 |
| PY2024 | Principal investigator | $2,487,242.40 | 90 |
| PY2023 | Principal investigator | $1,300,896.53 | 158 |
| PY2022 | Recipient | $477.67 | 2 |
| PY2022 | Principal investigator | $984,089.57 | 113 |
| PY2021 | Principal investigator | $953,202.96 | 94 |
| PY2020 | Principal investigator | $288,582.39 | 34 |
| PY2019 | Principal investigator | $661,080.71 | 44 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
94 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $49,405.70 | 12/23/2025 | Non-covered Recipient Entity NYU School Of Medicine Office | Phase I FIH study of BI 1810631 | No dispute reported | 06/30/2026 | 1220816640 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,672.00 | 12/05/2025 | Non-covered Recipient Entity NYU School Of Medicine Office | Phase I FIH study of BI 1810631 | No dispute reported | 06/30/2026 | 1220816638 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $647.06 | 12/05/2025 | Non-covered Recipient Entity NYU School Of Medicine Office | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220816706 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $39.85 | 12/01/2025 | Non-covered Recipient Entity NYU Langone Health | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577568 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $266,047.77 | 11/30/2025 | Non-covered Recipient Entity NYU Langone Health | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220995494 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $170,382.50 | 11/14/2025 | Non-covered Recipient Entity NYU School Of Medicine Office | Phase I FIH study of BI 1810631 | No dispute reported | 06/30/2026 | 1220816636 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,060.00 | 11/07/2025 | Non-covered Recipient Entity NEW YORK UNIVERSITY | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175312696 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,060.00 | 11/07/2025 | Non-covered Recipient Entity NEW YORK UNIVERSITY | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175312801 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $39.85 | 11/01/2025 | Non-covered Recipient Entity NYU Langone Health | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577566 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,928.00 | 10/09/2025 | Non-covered Recipient Entity NEW YORK UNIVERSITY | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175312544 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $39.85 | 10/01/2025 | Non-covered Recipient Entity NYU Langone Health | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577564 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $225,117.34 | 09/30/2025 | Non-covered Recipient Entity NYU Langone Health | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220995490 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $327,443.41 | 09/30/2025 | Non-covered Recipient Entity NYU Langone Health | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220995492 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $644.60 | 09/24/2025 | Non-covered Recipient Entity NYU Langone Health | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220995482 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $69.96 | 09/24/2025 | Non-covered Recipient Entity NYU Langone Health | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220995484 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $319.68 | 09/24/2025 | Non-covered Recipient Entity NYU Langone Health | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220995486 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $19.20 | 09/24/2025 | Non-covered Recipient Entity NYU Langone Health | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220995488 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,928.00 | 09/15/2025 | Non-covered Recipient Entity NEW YORK UNIVERSITY | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175313062 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,512.50 | 09/10/2025 | Non-covered Recipient Entity NYU School Of Medicine Office | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220816704 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $81,645.00 | 09/08/2025 | Non-covered Recipient Entity NYU School Of Medicine Office | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220816702 |
| Principal investigator 1 | Janssen Research & Development, LLC | $13,300.00 | 09/08/2025 | Non-covered Recipient Entity NEW YORK UNIVERSITY | An Open label Phase 11b Study to Evaluate the Safety and Pharmacokinetics of JNJ73841937 Lazertinib a Third Generation EGFRTKI as Monotherapy or in Combinations With JNJ61186372 a Human Bispecific EGFR and cMet Antibody in Participants With Advanced Non Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175312130 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $192,005.23 | 09/03/2025 | Non-covered Recipient Entity NYU School Of Medicine Office | Phase I FIH study of BI 1810631 | No dispute reported | 06/30/2026 | 1220816634 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $39.85 | 09/01/2025 | Non-covered Recipient Entity NYU Langone Health | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577562 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,702.00 | 09/01/2025 | Non-covered Recipient Entity NEW YORK UNIVERSITY | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175311939 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,805.00 | 09/01/2025 | Non-covered Recipient Entity NEW YORK UNIVERSITY | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175312717 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,588.24 | 08/20/2025 | Non-covered Recipient Entity NYU School Of Medicine Office | Phase I FIH study of BI 1810631 | No dispute reported | 06/30/2026 | 1220816632 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,651.00 | 08/18/2025 | Non-covered Recipient Entity NEW YORK UNIVERSITY | An Open label Phase 11b Study to Evaluate the Safety and Pharmacokinetics of JNJ73841937 Lazertinib a Third Generation EGFRTKI as Monotherapy or in Combinations With JNJ61186372 a Human Bispecific EGFR and cMet Antibody in Participants With Advanced Non Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175312551 |
| Principal investigator 1 | Janssen Research & Development, LLC | $16,086.00 | 08/18/2025 | Non-covered Recipient Entity NEW YORK UNIVERSITY | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175313157 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $39.85 | 08/01/2025 | Non-covered Recipient Entity NYU Langone Health | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577560 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $439.50 | 07/28/2025 | Non-covered Recipient Entity NYU Langone Health | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220995476 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $299.70 | 07/28/2025 | Non-covered Recipient Entity NYU Langone Health | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220995478 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $18.00 | 07/28/2025 | Non-covered Recipient Entity NYU Langone Health | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220995480 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,672.00 | 07/23/2025 | Non-covered Recipient Entity NYU School Of Medicine Office | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220816694 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,512.50 | 07/23/2025 | Non-covered Recipient Entity NYU School Of Medicine Office | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220816696 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,672.00 | 07/23/2025 | Non-covered Recipient Entity NYU School Of Medicine Office | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220816698 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $39,992.40 | 07/23/2025 | Non-covered Recipient Entity NYU School Of Medicine Office | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220816700 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,725.00 | 07/22/2025 | Non-covered Recipient Entity NEW YORK UNIVERSITY | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175313022 |
| Principal investigator 1 | Janssen Research & Development, LLC | $260.00 | 07/09/2025 | Non-covered Recipient Entity NEW YORK UNIVERSITY | An Open label Phase 11b Study to Evaluate the Safety and Pharmacokinetics of JNJ73841937 Lazertinib a Third Generation EGFRTKI as Monotherapy or in Combinations With JNJ61186372 a Human Bispecific EGFR and cMet Antibody in Participants With Advanced Non Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175312861 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,096.00 | 07/07/2025 | Non-covered Recipient Entity NEW YORK UNIVERSITY | An Open label Multi Center Dose Escalation Phase 1b Study to Assess the Safety and Pharmacokinetics of Subcutaneous Delivery of Amivantamab a Human Bispecific EGFR and cMet Antibody for the Treatment of Advanced Solid Malignancies | No dispute reported | 06/30/2026 | 1175311773 |
| Principal investigator 1 | Janssen Research & Development, LLC | $493.00 | 07/07/2025 | Non-covered Recipient Entity NEW YORK UNIVERSITY | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175312431 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $39.85 | 07/01/2025 | Non-covered Recipient Entity NYU Langone Health | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577558 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $54,104.00 | 07/01/2025 | Non-covered Recipient Entity NYU School Of Medicine Office | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220816692 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,617.70 | 06/30/2025 | Non-covered Recipient Entity NEW YORK UNIVERSITY | A Study of Combination Amivantamab and Carboplatin Pemetrexed Therapy Compared With Carboplatin Pemetrexed in Participants With Advanced or Metastatic Non Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor EGFR Exon 20 Insertions | No dispute reported | 06/30/2026 | 1175311850 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $18,150.75 | 06/27/2025 | Non-covered Recipient Entity NYU School Of Medicine Office | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220816688 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,102.95 | 06/27/2025 | Non-covered Recipient Entity NYU School Of Medicine Office | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220816690 |
| Principal investigator 1 | Janssen Research & Development, LLC | $10,002.50 | 06/23/2025 | Non-covered Recipient Entity NEW YORK UNIVERSITY | A Phase 3, Open-label, Randomized Study of Lazertinib with Subcutaneous Amivantamab Administered via Manual Injection Compared with Intravenous Amivantamab or Amivantamab Subcutaneous On Body Delivery System in Patients with EGFR-mutated Advanced or Meta | No dispute reported | 06/30/2026 | 1175312392 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,638.00 | 06/23/2025 | Non-covered Recipient Entity NEW YORK UNIVERSITY | A Phase 3, Open-label, Randomized Study of Lazertinib with Subcutaneous Amivantamab Administered via Manual Injection Compared with Intravenous Amivantamab or Amivantamab Subcutaneous On Body Delivery System in Patients with EGFR-mutated Advanced or Meta | No dispute reported | 06/30/2026 | 1175312755 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,725.00 | 06/09/2025 | Non-covered Recipient Entity NEW YORK UNIVERSITY | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175311897 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,479.00 | 06/09/2025 | Non-covered Recipient Entity NEW YORK UNIVERSITY | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175312654 |
| Principal investigator 1 | Janssen Research & Development, LLC | $16,354.00 | 06/09/2025 | Non-covered Recipient Entity NEW YORK UNIVERSITY | A Study of Combination Amivantamab and Carboplatin Pemetrexed Therapy Compared With Carboplatin Pemetrexed in Participants With Advanced or Metastatic Non Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor EGFR Exon 20 Insertions | No dispute reported | 06/30/2026 | 1175312971 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,491.40 | 06/05/2025 | Non-covered Recipient Entity NYU School Of Medicine Office | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220816684 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $338.00 | 06/05/2025 | Non-covered Recipient Entity NYU School Of Medicine Office | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220816686 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $39.85 | 06/01/2025 | Non-covered Recipient Entity NYU Langone Health | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577556 |
| Principal investigator 1 | Janssen Research & Development, LLC | $260.00 | 05/29/2025 | Non-covered Recipient Entity NEW YORK UNIVERSITY | An Open label Phase 11b Study to Evaluate the Safety and Pharmacokinetics of JNJ73841937 Lazertinib a Third Generation EGFRTKI as Monotherapy or in Combinations With JNJ61186372 a Human Bispecific EGFR and cMet Antibody in Participants With Advanced Non Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175311810 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,672.00 | 05/28/2025 | Non-covered Recipient Entity NYU School Of Medicine Office | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220816678 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $7,703.40 | 05/28/2025 | Non-covered Recipient Entity NYU School Of Medicine Office | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220816680 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $243.00 | 05/28/2025 | Non-covered Recipient Entity NYU School Of Medicine Office | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220816682 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $498.10 | 05/27/2025 | Non-covered Recipient Entity NYU Langone Health | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220995466 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $244.86 | 05/27/2025 | Non-covered Recipient Entity NYU Langone Health | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220995468 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $339.66 | 05/27/2025 | Non-covered Recipient Entity NYU Langone Health | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220995470 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $26.60 | 05/27/2025 | Non-covered Recipient Entity NYU Langone Health | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220995472 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $12.00 | 05/27/2025 | Non-covered Recipient Entity NYU Langone Health | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220995474 |
| Principal investigator 1 | Janssen Research & Development, LLC | $260.00 | 05/12/2025 | Non-covered Recipient Entity NEW YORK UNIVERSITY | An Open label Phase 11b Study to Evaluate the Safety and Pharmacokinetics of JNJ73841937 Lazertinib a Third Generation EGFRTKI as Monotherapy or in Combinations With JNJ61186372 a Human Bispecific EGFR and cMet Antibody in Participants With Advanced Non Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175311803 |
| Principal investigator 1 | Mirati Therapeutics, Inc. | $3,526.70 | 05/07/2025 | Non-covered Recipient Entity NYU Langone Hospitals - Tisch Hospitals Clinical Labs | A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL-1 | No dispute reported | 06/30/2026 | 1236530881 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $39.85 | 05/01/2025 | Non-covered Recipient Entity NYU Langone Health | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577554 |
| Principal investigator 1 | Janssen Research & Development, LLC | $67,468.00 | 05/01/2025 | Non-covered Recipient Entity NEW YORK UNIVERSITY | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175312772 |
| Principal investigator 1 | Eli Lilly and Company | $49,664.00 | 04/22/2025 | Non-covered Recipient Entity NEW YORK UNIVERSITY | SUNRAY-01 A GLOBAL PIVOTAL STUDY IN PARTICIPANTS WITH KRAS G12C-MUTANT LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER COMPARING FIRST LINE TREATMENT OF LY3537982 AND PEMBROLIZUMAB VS PLACEBO AND PEMBROLIZUMAB IN THOSE WITH PD L1 EXPRESSION 50% OR LY3537982 AND PEMBROLIZUMAB PEMETREXED PLATINUM VS PLACEBO AND PEMBROLIZUMAB PEMETREXED PLATINUM REGARDLESS OF PD-L1 EXPRESSION | No dispute reported | 06/30/2026 | 1187886410 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $9,266.40 | 04/17/2025 | Non-covered Recipient Entity NYU School Of Medicine Office | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220816674 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $43,580.00 | 04/17/2025 | Non-covered Recipient Entity NYU School Of Medicine Office | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220816676 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,550.00 | 04/03/2025 | Non-covered Recipient Entity NEW YORK UNIVERSITY | A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc | No dispute reported | 06/30/2026 | 1175311834 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $39.85 | 04/01/2025 | Non-covered Recipient Entity NYU Langone Health | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577552 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,137.00 | 03/31/2025 | Non-covered Recipient Entity NEW YORK UNIVERSITY | An Open label Phase 11b Study to Evaluate the Safety and Pharmacokinetics of JNJ73841937 Lazertinib a Third Generation EGFRTKI as Monotherapy or in Combinations With JNJ61186372 a Human Bispecific EGFR and cMet Antibody in Participants With Advanced Non Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175311741 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $351.60 | 03/25/2025 | Non-covered Recipient Entity NYU Langone Health | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220995460 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $128.26 | 03/25/2025 | Non-covered Recipient Entity NYU Langone Health | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220995462 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $119.88 | 03/25/2025 | Non-covered Recipient Entity NYU Langone Health | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220995464 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $39.85 | 03/01/2025 | Non-covered Recipient Entity NYU Langone Health | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577546 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $41.95 | 03/01/2025 | Non-covered Recipient Entity NYU Langone Health | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577548 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $48,662.00 | 03/01/2025 | Non-covered Recipient Entity NYU School Of Medicine Office | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220816672 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $498.10 | 02/25/2025 | Non-covered Recipient Entity NYU Langone Health | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220995454 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $339.66 | 02/25/2025 | Non-covered Recipient Entity NYU Langone Health | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220995456 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $20.40 | 02/25/2025 | Non-covered Recipient Entity NYU Langone Health | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220995458 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,285.20 | 02/24/2025 | Non-covered Recipient Entity NEW YORK UNIVERSITY | An Open label Phase 11b Study to Evaluate the Safety and Pharmacokinetics of JNJ73841937 Lazertinib a Third Generation EGFRTKI as Monotherapy or in Combinations With JNJ61186372 a Human Bispecific EGFR and cMet Antibody in Participants With Advanced Non Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175312580 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,794.00 | 02/20/2025 | Non-covered Recipient Entity NEW YORK UNIVERSITY | An Open label Phase 11b Study to Evaluate the Safety and Pharmacokinetics of JNJ73841937 Lazertinib a Third Generation EGFRTKI as Monotherapy or in Combinations With JNJ61186372 a Human Bispecific EGFR and cMet Antibody in Participants With Advanced Non Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175312603 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $7,501.95 | 02/02/2025 | Non-covered Recipient Entity NYU School Of Medicine Office | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220816668 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $9,592.05 | 02/02/2025 | Non-covered Recipient Entity NYU School Of Medicine Office | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220816670 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $39.85 | 02/01/2025 | Non-covered Recipient Entity NYU Langone Health | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577544 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $732.50 | 01/27/2025 | Non-covered Recipient Entity NYU Langone Health | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220995448 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $299.70 | 01/27/2025 | Non-covered Recipient Entity NYU Langone Health | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220995450 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $12.00 | 01/27/2025 | Non-covered Recipient Entity NYU Langone Health | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220995452 |
| Principal investigator 1 | Eli Lilly and Company | $6,723.25 | 01/27/2025 | Non-covered Recipient Entity NEW YORK UNIVERSITY | SUNRAY-01 A GLOBAL PIVOTAL STUDY IN PARTICIPANTS WITH KRAS G12C-MUTANT LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER COMPARING FIRST LINE TREATMENT OF LY3537982 AND PEMBROLIZUMAB VS PLACEBO AND PEMBROLIZUMAB IN THOSE WITH PD L1 EXPRESSION 50% OR LY3537982 AND PEMBROLIZUMAB PEMETREXED PLATINUM VS PLACEBO AND PEMBROLIZUMAB PEMETREXED PLATINUM REGARDLESS OF PD-L1 EXPRESSION | No dispute reported | 06/30/2026 | 1187884684 |
| Principal investigator 1 | Janssen Research & Development, LLC | $11,557.00 | 01/20/2025 | Non-covered Recipient Entity NEW YORK UNIVERSITY | An Open label Phase 11b Study to Evaluate the Safety and Pharmacokinetics of JNJ73841937 Lazertinib a Third Generation EGFRTKI as Monotherapy or in Combinations With JNJ61186372 a Human Bispecific EGFR and cMet Antibody in Participants With Advanced Non Small Cell Lung Cancer | No dispute reported | 06/30/2026 | 1175312448 |
| Principal investigator 1 | Mirati Therapeutics, Inc. | $22,375.40 | 01/15/2025 | Non-covered Recipient Entity NYU Langone Hospitals - Tisch Hospitals Clinical Labs | Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1 | No dispute reported | 06/30/2026 | 1236530877 |
| Principal investigator 1 | Eli Lilly and Company | $338,932.73 | 01/09/2025 | Non-covered Recipient Entity NEW YORK UNIVERSITY | A PHASE 1A/1B STUDY OF LY3537982 IN PATIENTS WITH KRAS G12C-MUTANT ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 1187886408 |
| Principal investigator 1 | Boehringer Ingelheim Espana S.A. | $39.85 | 01/01/2025 | Non-covered Recipient Entity NYU Langone Health | Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations | No dispute reported | 06/30/2026 | 1220577550 |